Genetic polymorphism of glutathione S-transferases M1 and T1 (GSTM1 and GSTT1) in the patients with non-hodgkin malignant lymphomas

Genetically determined differences in the activity of enzymes of the second phase of xenobiotic biotransformation can cause unequal predisposition to cancer, including non-Hodgkin lymphomas (NHL). The role of glutathione  S-transferases M1 and T1 (GSTM1 and GSTT1) in genetic susceptibility to NHL has been analyzed in the study. The association between the deletion in the gene GSTM1 and two-fold increased risk of indolent variants of the disease (OR = 1.96; C.I. [1.07–3.581], p < 0.02) has been revealed. There is no association with polymorphic genes GSTM1 and GSTT1 for aggressive lymphomas. Thus, these findings provide evidence that the genes of biotransformation GSTM1 and GSTT1 may play a role in the pathogenesis of non-Hodgkin lymphomas.

1. Atnyukova O.E., Pahomov A.Y., Handogina E.K. Polymorphisms of detoxification genes and the possible role of natural selection // Radiatsionnaya biologiya. Radioecologiya. 2009. 49. (5). 538–542. (in Russian)

2. Berezina O.V., Weiner A.S., Pospelova T.I. et al. Association of folate metabolism genes polymorphisms with risk of aggressive and indolent non-Hodgkin malignant lymphomas // Byulleten' Sibirskogo Otdeleniya Rossiyskoy Akademii Meditsinskikh Nauk. 2011. 31. (2). 20–25. (in Russian)

3. Volkova M.A. Clinical oncogematology. Moscow: Meditsina, 2007. 1120 p. (in Russian)

4. Voropaeva E.N., Skvortsova N.V., Voevoda M.I., Tarnovsky R.V. Clinical significance of CCR5 gene deletion at patients with non-Hodgkin lymphomas // Byulleten' Sibirskogo Otdeleniya Rossiyskoy Akademii Meditsinskikh Nauk. 2011. 31. (2). 26–30. (in Russian)

5. Dmitrieva A.I. Role of polymorphous genes of biotransformation xenobiotic system and p53 gene in pathogenesis of oncological diseases: abstract of thesis…doctor of medical sciences. Tomsk, 2009. (in Russian)

6. Mushkambarov N.N.Molecular biology. Moscow, 2007. 536 p. (in Russian)

7. Pospelova T.I., Voropaeva E.N., Voevoda M.I., Berezina O.V. P53 gene polymorphism as a potential marker of susceptibility to non-Hodgkin malignant lymphomas // Gematologiya i transfuziologiya. 2010. 55. (1). 11–17. (in Russian).

8. Agodi A., Barchitta M., Cipresso R. et al. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily // Int. J. Gynecol. Cancer. 2010. 20. (1). 141–146.

9. Avti P.K., Vaiphei K., Pathak C.M., Khanduja K.L. Involvement of various molecular events in cellular injury induced by smokeless tobacco // Chem. Res. Toxicol. 2010. 2. (7). 1163–1174.

10. Bellido M., Capello D., Altés A. et al. Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement // Haematologica. 2002. 87. (9). 908–917.

11. Carlsten C., Sagoo G.S., Frodsham A.J. et al. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis // Am. J. Epidemiol. 2008. 167. (7). 759–774.

12. Cho H.J., Eom H.S., Kim H.J. et al. Glutathione S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma // Cancer Genet. Cytogenet. 2010. 198. (1). 40–46.

13. Geisler S.A., Olshan A.F. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review // Am. J. Epidemiol. 2001. 154. (2). 95–105.

14. Ginsberg G., Smolenski S., Hattis D. et al. Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity // J. Toxicol. Environ. Health B. Crit. Rev. 2009. 12. (5–6). 389–439.

15. Hohaus S., Mansueto G., Massini G. et al. Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin’s Lymphoma // Leuk. Lymphoma. 2007. 48. (3). 564–569.

16. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review // Mutat. Res. 2000. 463. (3). 247–283.

17. Liu Y., Xu L.Z. Meta-analysis of association between GSTM1 gene polymorphism and cervical cancer // Asian Pac. J. Trop. Med. 2012. 5. (6). 480–484.

18. Ruiz-Cosano J., Conesa-Zamora P., Gon­zá­lez-Conejero R. et al. Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure // Mol. Carcinog. 2012. 51. (6). 508–513.

19. Sabbatini E., Bacci F., Sagramoso C., Pileri S. A. WHO classification of tumours of haematopoie­tic and lymphoid tissues in 2008: an overview // Pathologica. 2010. 102. (3). 83–87.

20. Vijayakrishnan J., Houlston R.S. Candidate ge­ne association studies and risk of childhood acute lym­phoblastic leukemia: a systematic review and meta-analysis // Haematologica. 2010. 95. (8). 1405–1414.

21. Wani M.A., Zhu Q., El-Mahdy M., Venka­ta­chalam S., Wani A.A. Enhanced sensitivity to anti-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells // Cancer Res. 2000. 60. (8). 2273–2280.

22. Weiner A.S., Beresina O.V., Voronina E.N. et al. Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin’s lymphoma // Leuk. Res. 2011. 35. (4). 508–515.

23. Zhang Z., Deng X., Ren X. et al. Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma // Scand. J. Gastroenterol. 2010. 45. (7–8). 925–934.

24.          Zhu Y., He Q., Wang J., Pan H.F. The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis // Mol. Biol. Rep. 2012. 39. (1). 685–691.

Filipenko M.L. – candidate of biological sciences, head of the pharmacogenomic group, e-mail: max@niboch.nsc.ru